BG102669A - Method of treatment and pharmaceutical composition - Google Patents

Method of treatment and pharmaceutical composition Download PDF

Info

Publication number
BG102669A
BG102669A BG102669A BG10266998A BG102669A BG 102669 A BG102669 A BG 102669A BG 102669 A BG102669 A BG 102669A BG 10266998 A BG10266998 A BG 10266998A BG 102669 A BG102669 A BG 102669A
Authority
BG
Bulgaria
Prior art keywords
phenyl
sodium
loratadine
leukotriene antagonist
composition according
Prior art date
Application number
BG102669A
Other languages
Bulgarian (bg)
Inventor
Sven-Erik Dahlen
Edward Scolnick
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG102669A publication Critical patent/BG102669A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

The invention relates to a method for the treatment ofasthma, allergy and inflammations where leukotriene inhibitor andloratadin are administered either simultaneously or as individualdoses, or combined in an individual pharmaceutical form.12 claims

Description

Област на техникатаTechnical field

Настоящата заявка претендира за приоритета на заявка номер 60/011,328, подадена на 8 февруари 1996.This application claims the priority of application number 60 / 011,328, filed February 8, 1996.

Предшестващо състояние на техникатаBACKGROUND OF THE INVENTION

Лоратадинът е антихистамин с антагонистични свойства по отношение на Н-рецептора и е полезен за лечение на алергии. Описан е в U.S.Patent 4,282,233.Loratadine is an antihistamine with antagonistic properties against the H-receptor and is useful for the treatment of allergies. It is described in U.S. Patent 4,282,233.

Известно е, че лейкотриеновите антагонисти са полезни при лечението на астма, алергични реакции и възпаление.Leukotriene antagonists are known to be useful in the treatment of asthma, allergic reactions and inflammation.

С настоящето изобретение се предоставя метод за лечение на астма, алергия и възпаление с комбинация от тези две средства, която е по-ефикасна от всяко от тях само по себе си.The present invention provides a method of treating asthma, allergy and inflammation with a combination of these two agents that is more effective than either of these in itself.

Същност на техникатаThe essence of the technique

Изобретението се отнася до метод за лечение на астма, алергия и възпаление чрез прилагане на ефективно количество от лоратадин и ефективно количество от лейкотриенов антагонист или чрез съвместното им приемане, или комбинирани в единичен фармацевтичен състав, в който лейкотриеновият антагонист е избран от:The invention relates to a method of treating asthma, allergy and inflammation by administering an effective amount of loratadine and an effective amount of a leukotriene antagonist, or by co-administration thereof, or combined into a single pharmaceutical composition in which the leukotriene antagonist is selected from:

А. Натриев 1-(((К)-(3-(2-(7-хлоро-2-хинолинил)етенил)фенил)-3-(2(2-хидрокси-2-пропил)фенил)тио)метил)циклопропанацетат, ЕР 480,717A. Sodium 1 - ((((R) - (3- (2- (7-chloro-2-quinolinyl) ethenyl) phenyl) -3- (2 (2-hydroxy-2-propyl) phenyl) thio) methyl) cyclopropanacetate, EP 480,717

Натриев монтелукастMontelukast sodium

В. Натриев 1-(((К)-(3-(2-(6,7-дифлуоро-2-хинолинил)етенил)фенил)-3-(2-(2-хидрокси-2-пропил)фенил)тио)метил)циклопропанацетат. U.S. 5,270,324B. Sodium 1 - ((((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio ) methyl) cyclopropanacetate. U.S. No. 5,270,324

С. 1-(((1(К)-(3-(2-(2,3-дихлоротиено[3,2-Ь]-пиридин-5-ил)-(Е)етенил)фенил)-3-(2-( 1-хидрокси- 1-метилетил)фенил)пропил)тио)метил)циклопропаноцешна киселина или нейна натриева сол. U.S. 5,472,964C. 1 - ((((1 (R) - (3- (2- (2,3-dichlorothieno [3,2-b] -pyridin-5-yl) - (E) ethenyl) phenyl) -3- ( 2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropanoic acid or its sodium salt. U.S. No. 5,472,964

D. №-[4-оксо-2-(1Н-теп1разол-5-ил)-4Н-1-бензопиран-8-ил]-р-(4фенилбутокси)бензамид. ЕР 173,516D. N- [4-Oxo-2- (1H-teprazol-5-yl) -4H-1-benzopyran-8-yl] -p- (4-phenylbutoxy) benzamide. EP 173,516

ОOh

ПранлукастPranlukast

Е. Циклопентил-3-[2-метокси-4-[(о-толилсулфонил)карбамоил]бензил]-1-метилиндол-5-карбамат. ЕР 199,543E. Cyclopentyl-3- [2-methoxy-4 - [(o-tolylsulfonyl) carbamoyl] benzyl] -1-methylindole-5-carbamate. EP 199,543

ЗафирлукастZafirlukast

Подробно описание на изобретениетоDetailed description of the invention

Новият фармацевтичен състав от настоящето изобретение включва като активна съставка комбинация от лоратадин иThe new pharmaceutical composition of the present invention includes as active ingredient a combination of loratadine and

лейкотриенов антагонист, избран от описаните по-горе А, В, С, D и Е и евентуално фармацевтично приемлив носител, подходящ за ентерално и парентерално прилагане. Съставите могат да бъдат в твърда форма, например като таблетки или капсули, или в течна форма, например сиропи, елексири, емулсии и инжекционни. При формулирането на фармацевтични дозирани форми обикновено се използват помощни средства като вода, желатин, лактозни нишестета, магнезиев стеарат, талк, растителни масла, бензилов алкохол, смоли, полиалкиленгликоли и вазелин. Една предпочитана форма е по-пълно описана в следващия пример.a leukotriene antagonist selected from the above A, B, C, D and E and optionally a pharmaceutically acceptable carrier suitable for enteral and parenteral administration. The compositions may be in solid form, for example as tablets or capsules, or in liquid form, for example syrups, elixirs, emulsions and injectables. Formulations of pharmaceutical dosage forms generally use adjuvants such as water, gelatin, lactose starch, magnesium stearate, talc, vegetable oils, benzyl alcohol, resins, polyalkylene glycols and petrolatum. A preferred form is more fully described in the following example.

В новия метод за лечение от настоящето изобретение лоратадинът и лейкотриеновия антагонист основно се прилагат съвместно като отделни дозирани форми или комбинирани в новия фармацевтичен състав от изобретението.In the new method of treatment of the present invention, loratadine and the leukotriene antagonist are generally co-administered as separate dosage forms or combined in the new pharmaceutical composition of the invention.

Въпреки че необходимата доза се определя от такива фактори като възраст, пол, тегло на пациента и острота на състоянието, което ще бъде лекувано, предпочитаната орална дозировка за хора е в интервала от 5 до 20 mg лоратадин 1 до 3 пъти дневно; за предпочитане около 10 mg веднаж на ден. В случая с лейкотриените дозировката за хора е също в интервала от около 5 до 20 mg 1 до 3 пъти дневно, за предпочитане около 10 mg веднаж на ден.Although the required dose is determined by factors such as age, sex, weight of the patient and the severity of the condition to be treated, the preferred oral oral dosage for humans is in the range of 5 to 20 mg loratadine 1 to 3 times daily; preferably about 10 mg once a day. In the case of leukotrienes, human dosage is also in the range of about 5 to 20 mg 1 to 3 times daily, preferably about 10 mg once daily.

Пример за изпълнение на изобретениетоAn embodiment of the invention

Натриев монтелукаст 10 mg и Лоратадин 10 mg - филмтаблеткаMontelukast 10 mg sodium and Loratadine 10 mg film-coated tablet

Количество на 1 таблетка Quantity of 1 tablet Съставка Ingredient Сърцевина The core 10.4 mg 10.4 mg Натриев монтелукаст Montelukast sodium 10.0 mg 10.0 mg Лоратадин Loratadine 66.6 mg 66.6 mg Микрокристална целулоза, NF Microcrystalline cellulose, NF 100.0 mg 100.0 mg Лактоза монохидрат, NF Lactose monohydrate, NF 6.0 mg 6.0 mg Натриева кроскармелоза, NF Croscarmellose sodium, NF (60.0 mg) (60.0 mg) Пречистена вода, USP Purified water, USP 1.0 mg 1.0 mg Магнезиев стеарат, NF Magnesium stearate, NF 200.0 mg 200.0 mg Сърцевина на таблетката The core of the tablet филмово movie покритие cover 2.25 mg 2.25 mg Хидроксипропилметилцелулоза 6 cps Hydroxypropyl methylcellulose 6 cps 1.25 mg 1.25 mg Хидроксипропилцелулоза LF Hydroxypropylcellulose LF 1.50 mg 1.50 mg Титандиоксид Titanium dioxide (33.5) mg (33.5) mg Пречистена вода Purified water 205.0 205.0 Филм-таблетка Film tablet

·· ······ ····

Claims (12)

ПАТЕНТНИ ПРЕТЕНЦИИPatent Claims 1. фармацевтичен състав, характеризиращ се с това, че съдържа като активна съставка лоратадин и лейкотриенов антагонист, избран от:A pharmaceutical composition comprising, as active ingredient, loratadine and a leukotriene antagonist selected from: (A) натриев монтелукаст;(A) sodium montelukast; (B) Натриев 1-(((К)-(3-(2-(6,7-дифлуоро-2-хинолинил)етенил)фенил)-3-(2-(2-хидрокси-2-пропил)фенил)тио)метил)циклопропанацетат;(B) Sodium 1 - ((((R) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio) methyl) cyclopropanacetate; (C) 1-((( 1(К)-(3-(2-(2,3-дихлоротиено[3,2-Ь]-пиридин-5-ил)-(Е)етенил)фенил)-3-(2-( 1-хидрокси- 1-метилетил)фенил)пропил)тио)метил)циклопропаноцетна киселина или нейна натриева сол;(C) 1 - ((((1 (K) - (3- (2- (2,3-dichlorothieno [3,2-b] -pyridin-5-yl) - (E) ethenyl) phenyl) -3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropanoic acid or its sodium salt; (D) пранлукаст; и (E) зафирлукаст;(D) pranlukast; and (E) zafirlukast; и фармацевтично приемлив носител.and a pharmaceutically acceptable carrier. 2. Състав съгласно претенция 1, характеризиращ се с това, че е предназначен за орално приемане.Composition according to claim 1, characterized in that it is intended for oral administration. 3. Състав съгласно претенция 2, характеризиращ се с това, че съдържа 10 mg лоратадин и 10 mg лейкотриенов антагонист, избран от (А), (В), (С), (D) и (Е).Composition according to claim 2, characterized in that it contains 10 mg loratadine and 10 mg leukotriene antagonist selected from (A), (B), (C), (D) and (E). 4. Състав съгласно претенция 1, характеризиращ се с това, че лейкотриеновият антагонист е натриев монтелукаст.Composition according to claim 1, characterized in that the leukotriene antagonist is sodium montelukast. 5. Състав съгласно претенция 4, характеризиращ се с това, че е предназначен за орално приемане.Composition according to claim 4, characterized in that it is intended for oral administration. 6. Състав съгласно претенция 5, характеризиращ се с това, че съдържа по 10 mg от всяка активна съставка.Composition according to claim 5, characterized in that it contains 10 mg of each active ingredient. 7. Метод за лечение на астма, алергия и възпаление у пациенти, нуждаещи се от такова лечение, чрез прилагане на ·· ·· • · ·· ·· ·· ··· • · ·· ·· • · • · ·· ефективно количество лоратадин и ефективно количество лейкотриенов антагонист, избран от:7. A method for the treatment of asthma, allergy and inflammation in patients in need of such treatment by administering · · · · · · · · · · · · · · · an effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: (A) натриев монтелукаст;(A) sodium montelukast; (B) Натриев 1-(((К.)-(3-(2-(6,7-дифлуоро-2-хинолинил)етенил)фенил)-3-(2-(2-хидрокси-2-пропил)фенил)тио)метил)циклопропанацетат;(B) Sodium 1 - ((((K.)) - (3- (2- (6,7-difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl ) thio) methyl) cyclopropanacetate; (C) 1-((( 1(К)-(3-(2-(2,3-дихлоротиено[3,2-Ь]-пиридин-5-ил)-(Е)етенил)фенил)-3-(2-( 1-хидрокси- 1-метилетил)фенил)пропил)тио)метил)циклопропаноцетна киселина или нейна натриева сол:(C) 1 - ((((1 (K) - (3- (2- (2,3-dichlorothieno [3,2-b] -pyridin-5-yl) - (E) ethenyl) phenyl) -3- (2- (1-hydroxy-1-methylethyl) phenyl) propyl) thio) methyl) cyclopropanoic acid or its sodium salt: (D) пранлукаст; и (E) зафирлукаст;(D) pranlukast; and (E) zafirlukast; или съвместно като отделни дозирани форми или комбинирани в единичния фармацевтичен състав от претенция 1.or together as separate dosage forms or combined in the single pharmaceutical composition of claim 1. 8. Метод съгласно претенция 7, при който фармацевтичната форма е предназначена за орално приемане.The method of claim 7, wherein the pharmaceutical form is for oral administration. 9. Метод съгласно претенция 7, при който отделните дозирани форми и единичната фармацевтична форма съдържат 10 mg лоратадин и 10 mg лейкотриенов антагонист, избран от (А), (В), (С), (D) и (Е)The method of claim 7, wherein the individual dosage forms and the unit dosage form contain 10 mg loratadine and 10 mg leukotriene antagonist selected from (A), (B), (C), (D) and (E) 10. Метод съгласно претенция 7, при който лейкотриеновият антагонист е (А) натриев монтелукаст.The method of claim 7, wherein the leukotriene antagonist is (A) sodium montelukast. 11. Метод съгласно претенция 10, при който отделните дозирани форми и единичната фармацевтична форма са предназначени за орално приемане.The method of claim 10, wherein the individual dosage forms and the unit dosage form are for oral administration. 12. Метод съгласно претенция 11, при който отделните дозирани форми и единичната фармацевтична форма съдържат 10 mg лоратадин и 10 mg (А) натриев монтелукаст.The method of claim 11, wherein the individual dosage forms and the unit dosage form contain 10 mg loratadine and 10 mg (A) montelukast sodium.
BG102669A 1996-02-08 1998-08-05 Method of treatment and pharmaceutical composition BG102669A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion

Publications (1)

Publication Number Publication Date
BG102669A true BG102669A (en) 1999-04-30

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102669A BG102669A (en) 1996-02-08 1998-08-05 Method of treatment and pharmaceutical composition

Country Status (19)

Country Link
EP (1) EP1014972A4 (en)
JP (1) JPH11504044A (en)
KR (1) KR19990082367A (en)
CN (1) CN1210465A (en)
AU (1) AU732671B2 (en)
BG (1) BG102669A (en)
BR (1) BR9707369A (en)
CA (1) CA2245162A1 (en)
CZ (1) CZ248798A3 (en)
EE (1) EE9800234A (en)
IL (1) IL125446A0 (en)
IS (1) IS4805A (en)
NO (1) NO983641L (en)
NZ (1) NZ331160A (en)
PL (1) PL328074A1 (en)
SK (1) SK105698A3 (en)
TR (1) TR199801511T2 (en)
WO (1) WO1997028797A1 (en)
YU (1) YU33298A (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
CN1283115A (en) * 1997-12-23 2001-02-07 先灵公司 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
ID29137A (en) * 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
AR022378A1 (en) * 1998-09-10 2002-09-04 Schering Corp METHODS AND COMPOSITIONS TO TREAT SINUSITIS, MEDIUM OTITIS AND OTHER RELATED DISORDERS USING ANTIHISTAMINS
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (en) * 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
WO2004087095A2 (en) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Osmotic controlled release device containing zafirlukast and an h1-antagonist
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
WO2006047427A1 (en) 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
AR077101A1 (en) 2009-06-16 2011-08-03 Schering Corp STEROIDS OF HETEROARILO (3,2-C), AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES OF THE SAME
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation
JP2022516729A (en) * 2019-01-10 2022-03-02 ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド New formulation containing leukotriene receptor antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
PL328074A1 (en) 1999-01-04
IL125446A0 (en) 1999-03-12
BR9707369A (en) 1999-07-20
TR199801511T2 (en) 1998-10-21
YU33298A (en) 1999-11-22
AU732671B2 (en) 2001-04-26
NZ331160A (en) 2000-07-28
JPH11504044A (en) 1999-04-06
SK105698A3 (en) 1999-05-07
IS4805A (en) 1998-07-22
EE9800234A (en) 1998-12-15
NO983641D0 (en) 1998-08-07
KR19990082367A (en) 1999-11-25
AU2257997A (en) 1997-08-28
WO1997028797A1 (en) 1997-08-14
CN1210465A (en) 1999-03-10
EP1014972A1 (en) 2000-07-05
CA2245162A1 (en) 1997-08-14
CZ248798A3 (en) 1999-01-13
EP1014972A4 (en) 2004-12-08
NO983641L (en) 1998-08-07

Similar Documents

Publication Publication Date Title
BG102669A (en) Method of treatment and pharmaceutical composition
EP3054952B1 (en) Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
TWI389689B (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
RU2441655C2 (en) Kappa-opioid agonists for treatment of diarrhea-prevailing irritable bowel syndrome and alternate irritable bowel syndrome
AU1907199A (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
KR20020083161A (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
JPH01503539A (en) Cough/cold mixtures containing non-sedating antihistamines
CZ20023381A3 (en) Compound pharmaceutical preparations containing AT1-receptor antagonist and/or HMG-CoA reductase and/or ACE inhibitor
JP2001517639A (en) Use of a combination comprising a non-sedating antihistamine and an α-adrenergic agonist for the topical treatment of rhinitis / conjunctivitis and cold, cold-like and / or epidemic cold symptoms
EA003142B1 (en) Pharmaceutical composition with an antidepressive effect use thereof and method for treating
US20080026054A1 (en) Novel anelgesic combination
US20080031950A1 (en) Novel anelgesic combination
US20090118211A1 (en) Compositions and Methods for Enhancement of Sexual Function
WO2019139244A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
TW201442710A (en) Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof
WO2016120787A1 (en) Oral n-acetylcysteine in the treatment of upper respiratory tract infections and symptoms
US4794112A (en) Acetaminophen/hydroxyzine analgesic combinations
WO2002049670A1 (en) Preventives or remedies for endometriosis
EA022060B1 (en) Compound for treating infectious diseases, corresponding method, and pharmaceutical composition comprising said compound
CN111093647A (en) Statin compositions and methods for treating synucleinopathies
US20070275996A1 (en) Use of Statins For The Treatment Of Metabolic Syndrome
CN114569608A (en) Thromboxane receptor antagonists in AERD/asthma
EP4344701A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
JPH10120592A (en) Therapeutic agent for meniere's disease or meniere's syndrome
IL292882A (en) Dosing of a bruton's tyrosine kinase inhibitor